Cytokine polymorphisms and genotypic susceptibility of HCV infection in ribavirin response to peg interferon

被引:1
|
作者
Mohammad, Y. A. [1 ]
Mohammed, A. [1 ]
Muath, S. [1 ]
机构
[1] King Khalid Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Abha 61413, Saudi Arabia
关键词
HCV genotypes; cytokines; polymorphisms; ribavirin; peg interferon; HEPATITIS-C VIRUS; IL28B POLYMORPHISM; GENE POLYMORPHISM; EPIDEMIOLOGY; ASSOCIATION; FIBROSIS; THERAPY; IMPACT; IL-10; RISK;
D O I
10.47665/tb.40.3.009
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Immune responses are largely regulated by cytokines. Genetic polymorphisms of the regulatory coding regions are recognized to impact the expression of cytokines. The abnormal cytokine levels in hepatitis C virus (HCV) infection seems to be involved in disease progression, viral survival, and therapeutic response. The current study assesses the polymorphisms associated with IL-6, IL-10, IL28B, IFN-gamma, TGF-beta, and TNF-alpha on the genotypic susceptibility to HCV infection and Ribavirin response to Peg interferon. Droplet digital polymerase chain reaction (PCR) was used to assess the gene polymorphisms associated with IL-6 A/G (rs2069837), IL-10-1082 G/A (rs1800896)], IL28B C/T (rs12979860), IFN-gamma +874 A/T (rs2430561), TGF-beta 1-509 C/T (rs1800469) and TNF-alpha-308 G/A promoter (rs1800629) from stored samples of 200 healthy individuals and 300 HCV infected patients. There was a significant association of AG and AA genotypes of IL28B, IFN-gamma, TGF-beta 1, and TNF-alpha over HCV susceptibility and treatment outcome. However, no association between IL-6 and IL-10 gene polymorphism to HCV susceptibility response to the treatment. The observations indicate IL28B CT, TGF-beta 1 CT, TT and TNF- AG with AA genotypes influence the cytokine expression, which is related to susceptibility and resistance to HCV infection and combined antiviral therapy.
引用
收藏
页码:331 / 336
页数:6
相关论文
共 50 条
  • [21] ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection
    Asselah, Tarik
    Zeuzem, Stefan
    Soriano, Vicente
    Bronowicki, Jean-Pierre
    Lohse, Ansgar W.
    Muellhaupt, Beat
    Schuchmann, Marcus
    Bourliere, Marc
    Buti, Maria
    Roberts, Stuart K.
    Gane, Edward J.
    Stern, Jerry O.
    Voss, Florian
    Baum, Patrick
    Gallivan, John-Paul
    Boecher, Wulf O.
    Mensa, Federico J.
    PLOS ONE, 2015, 10 (12):
  • [22] Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin
    Sakr, Amany A.
    Ahmed, Amr E.
    Abd El-Maksoud, Mohamed D. E.
    Gamal, Amany
    El-garem, Hasan
    Ahmed, Osama M.
    INFECTION GENETICS AND EVOLUTION, 2020, 86
  • [23] Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study
    Terrier, Benjamin
    Lapidus, Nathanael
    Pol, Stanislas
    Serfaty, Lawrence
    Ratziu, Vlad
    Asselah, Tarik
    Thibault, Vincent
    Souberbielle, Jean-Claude
    Carrat, Fabrice
    Cacoub, Patrice
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (18) : 5647 - 5653
  • [24] HCV treatment with pegylated interferon and ribavirin in patients with haemophilia and HIV/HCV co-infection
    Denholm, J. T.
    Wright, E. J.
    Street, A.
    Sasadeusz, J. J.
    HAEMOPHILIA, 2009, 15 (02) : 538 - 543
  • [25] Influence of the HCV Subtype on the Virological Response to Pegylated Interferon and Ribavirin Therapy
    Legrand-Abravanel, Florence
    Colson, Philippe
    Leguillou-Guillemette, Helene
    Alric, Laurent
    Ravaux, Isabelle
    Lunel-Fabiani, Francoise
    Bouviers-Alias, Magali
    Trimoulet, Pascale
    Chaix, Marie Laure
    Hezode, Christophe
    Foucher, Juliette
    Fontaine, Helene
    Roque-Afonso, Anne-Marie
    Gassin, Michele
    Schvoerer, Evelyne
    Gaudy, Catherine
    Roche, Bruno
    Doffoel, Michel
    D'Alteroche, Louis
    Vallet, Sophie
    Baazia, Yazid
    Pozzetto, Bruno
    Thibault, Vincent
    Nousbaum, Jean-Baptiste
    Roulot, Dominique
    Coppere, Henry
    Poinard, Thierry
    Payan, Christopher
    Izopet, Jacques
    JOURNAL OF MEDICAL VIROLOGY, 2009, 81 (12) : 2029 - 2035
  • [26] Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience
    Waldenstrom, Jesper
    Farkkila, Martti
    Rembeck, Karolina
    Norkrans, Gunnar
    Langeland, Nina
    Morch, Kristine
    Pedersen, Court
    Rauning Buhl, Mads
    Nieminen, Urpo
    Nuutinen, Hannu
    Alsio, Asa
    Holmstrom, Lars
    Jungnelius, Rolf
    Lund, Katarina
    Rubensson, Anders
    Torell, Erik
    Westin, Johan
    Lagging, Martin
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (03) : 337 - 343
  • [27] Regulation of the Interferon Response by lncRNAs in HCV Infection
    Valadkhan, Saba
    Fortes, Puri
    FRONTIERS IN MICROBIOLOGY, 2018, 9
  • [28] Polymorphisms of HLA-DM on Treatment Response to Interferon/Ribavirin in Patients with Chronic Hepatitis C Virus Type 1 Infection
    Chen, Hongbo
    Yao, Yinan
    Wang, Yifan
    Zhou, Hua
    Xu, Tianxiang
    Liu, Jing
    Wang, Guocheng
    Zhang, Yongfeng
    Chen, Xiang
    Liu, Qingwei
    Huang, Peng
    Yu, Rongbin
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2016, 13 (10):
  • [29] Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: Early effects of active substance use
    Hotho, Daphne M.
    Kreefft, Kim
    Groothuismink, Zwier M. A.
    Janssen, Harry L. A.
    de Knegt, Robert J.
    Boonstra, Andre
    ANTIVIRAL RESEARCH, 2013, 97 (03) : 347 - 355
  • [30] Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study
    Anagnostou, O.
    Manolakopoulos, S.
    Bakoyannis, G.
    Papatheodoridis, G.
    Zisouli, A.
    Raptopoulou-Gigi, M.
    Manesis, E.
    Ketikoglou, I
    Dalekos, G.
    Gogos, C.
    Vassiliadis, T.
    Tzourmakliotis, D.
    Karatapanis, S.
    Kanatakis, S.
    Zoumpoulis-Vafiadis, I
    Hounta, A.
    Koutsounas, S.
    Giannoulis, G.
    Tassopoulos, N.
    Touloumi, G.
    HIPPOKRATIA, 2014, 18 (01) : 57 - 64